Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

0.5662 -0.0218 (-3.71%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 108,033
Open 0.5710
Bid (Size) 0.5662 (15)
Ask (Size) 0.5706 (1)
Prev. Close 0.5880
Today's Range 0.5650 - 0.5801
52wk Range 0.5000 - 4.170
Shares Outstanding 42,748,364
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For November 14, 2024
Via Benzinga
What's Next: BioXcel Therapeutics's Earnings Preview
Via Benzinga

Performance

YTD
-80.68%
-80.68%
1 Month
+3.10%
+3.10%
3 Month
-16.80%
-16.80%
6 Month
-71.26%
-71.26%
1 Year
-85.48%
-85.48%

More News

Read More
BTAI Stock Earnings: BioXcel Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
BioXcel Therapeutics's Earnings Outlook
Via Benzinga
AI Surge Has Ended: All 7 AI Stock Categories Declined This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
Earnings Scheduled For March 12, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
Via Get News
Why BioXcel Therapeutics Shares Are Rising Tuesday
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.